Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer

Cancer

Volumn 116, Issue SUPPL. 4, 2010, Pages 1118-1125

  Kraeber Bodéré, Françoise ^a,b   Salaun, Pierre Yves ^a   Oudoux, Aurore ^a   Goldenberg, David M ^c   Chatal, Jean François ^b   Barbet, Jacques ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Calcitonin; Carcinoembryonic antigen; Medullary thyroid carcinoma; Pretargeting; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY F 6734; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; DI PENTETIC ACID I 131; F(AB'') 2 FRAGMENT I 131; FLUORODEOXYGLUCOSE; HAPTEN; IMATINIB; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MN 14; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MN 14; MOTESANIB; PENTETIC ACID DERIVATIVE; PENTETIC ACID I 131 HAPTEN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

BLOOD TOXICITY; CANCER DIAGNOSIS; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSIMETRY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INHIBITION; DRUG SAFETY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LARYNGEAL MUCOSA SWELLING; LIVER METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; THYROID MEDULLARY CARCINOMA; THYROID SURGERY; TREATMENT DURATION; TUMOR VOLUME;

CARCINOMA, MEDULLARY; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; RADIOIMMUNOTHERAPY; RISK; SURVIVAL ANALYSIS; THYROID NEOPLASMS;

EID: 76249086341     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24800     Document Type: Conference Paper

References (42)

1. Tubiana M, Milhaud G, Coutris G, Lacour J, Parmentier C, Bok B. Medullary carcinoma and thyrocalcitonin. BMJ. 1968;4:87-89.
2. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029-2034.
3. Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg. 2008;32:754-765.
4. Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary thyroid carcinoma of the thyroid. Cancer. 1997;79:132-138.
5. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol. 1998;48:265-273.
6. Miccoli P, Minuto MN, Ugolini C, et al. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer. 2007;14:1099-1105.
7. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148.
8. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033-1041.
9. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682-687.
10. Ito Y, Yoshida H, Tomoda C. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. Cancer Lett. 2005;229:291-297.
11. Tisell LE, Oden A, Muth A, et al. The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer. 2003;89:2093-2097.
12. Barbet J, Campion L, Kraeber-Bodere F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077-6084.
13. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-1711.
14. Oudoux A, Salaun PY, Bournaud C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590-4597.
15. Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185-4190.
16. Mirallie E, Vuillez JP, Bardet S, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779-788.
17. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70-78.
18. Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;1:64-71.
19. 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer. 1999;85:1828-1842.
20. 2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med. 2000;41:93-103.
21. Barbet J, Kraeber-Bodere F, Vuillez JP, et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999;14:153-166.
22. De Santis R, Anastasi AM, D'Alessio et al. Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT). Br J Cancer. 2003;88:996-1003.
23. Hosono M, Hosono M, Kraeber-Bodere F, et al. Biodistribution and dosimetry study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. J Nucl Med. 1998;39:1608-1613.
24. Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maurel C, et al. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J Nucl Med. 1999;40:198-204.
25. Mirallie E, Sai-Maurel C, Faivre-Chauvet A, et al. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. Eur J Nucl Med Mol Imaging. 2005;32:901-909.
26. 2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res. 1999;5:3183s-3189s.
27. Bardies M, Bardet S, Faivre-Chauvet A, et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med. 1996;37:1853-1859.
28. Thomas SR, Maxon MR, Kereiakes JG, et al. Quantitative external counting techniques enabling improved diagnostic and therapy decisions in patients with well-differentiated thyroid cancer. Radiology. 1977;122:731-737.
29. Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999;5:3190s-3198s.
30. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, et al. Pharmacokinetics and dosimetry studies for optimisation of carcinoembryonic antigen x anti-hapten bispecific antibody mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 2003;9:3973-3981.
31. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131-I-labeled bivalent hapten in a phase I optimisation clinical trial. J Nucl Med. 2006;47:247-255.
32. Shimaoka K, Schoenfeld DA, Dewwys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155-2160.
33. Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:2496-2499.
34. Lorenz K, Brauckhoff M, Behrmann C, et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery. 2005;138:986-993.
35. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret proto-oncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996;81:1619-1622.
36. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13:535-540.
37. de Groot JWB, Zonnenberg BA, Quarles van Ufford-Mannesse P, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3466-3469.
38. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007;157:215-220.
39. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4701-4704.
40. Kober F, Hermann M, Handler A, Krotia G.Effect of sorafenib in symptomatic metastatic medullary thyroid cancer [abstract]. J Clin Oncol. 2007;2S:14065.
41. Wells SA, Gosnell JE, Gagel RF, et al.Vandetinib in metastatic medullary thyroid cancer: follow-up results of an open-label phase II trial [abstract]. J Clin Oncol. 2007;2S:6018.
42. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008; 4:22-32.